이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

China Resources Double-Crane PharmaceuticalLtd 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	3.4yrs
이사회 평균 재임 기간	2.9yrs

최근 관리 업데이트

Recent updates

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 24

Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel

Mar 02

CEO

China Resources Double-Crane PharmaceuticalLtd 에는 CEO가 없거나 그에 대한 데이터가 없습니다.

리더십 팀

이름	위치	테뉴어	보상	소유권
Hekai Tan	VP & Company Secretary	no data	CN¥1.11m	0.014% CN¥ 2.7m
Ziqin Liu	Vice President	3.4yrs	CN¥1.60m	0.018% CN¥ 3.5m
Chao Man	Vice President	3.4yrs	CN¥1.80m	0.025% CN¥ 4.9m
Donghan Yao	Vice President	1.4yrs	CN¥923.00k	데이터 없음

3.4yrs

평균 재임 기간

50yo

평균 연령

경험이 풍부한 관리: 600062 의 관리팀은 경험 ( 3.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Xiangming Li	Director	2.8yrs	데이터 없음	데이터 없음
Ning Liu	Independent Director	3yrs	CN¥150.00k	데이터 없음
Maozhu Sun	Independent Director	3yrs	CN¥150.00k	데이터 없음
Na Tang	Chairman of the Supervisory Board	3yrs	데이터 없음	데이터 없음
Wenchao Lu	Chairman of the board	1.9yrs	CN¥2.32m	0.024% CN¥ 4.7m
Cailian Kang	Independent Director	6.1yrs	CN¥150.00k	데이터 없음
Zheng Wei	Independent Director	6.1yrs	CN¥150.00k	데이터 없음
Zhanfeng Yang	Director	3yrs	데이터 없음	데이터 없음
Xiaosong Bai	Director	2.3yrs	데이터 없음	데이터 없음
Shutian Yu	Director	1.6yrs	데이터 없음	데이터 없음
Hui Xu	Director	less than a year	데이터 없음	데이터 없음
Guolong Lin	Director	less than a year	데이터 없음	데이터 없음

2.9yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: 600062 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

China Resources Double-Crane PharmaceuticalLtd 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 23, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.36 in 1Q 2023)

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel

Now 20% undervalued

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.24 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.40 in 2Q 2022)

Price target increased by 26% to CN¥24.32

Investor sentiment improves as stock rises 18%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target increased to CN¥19.26

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.28 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.30 in 2Q 2021)

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd. for RMB 501.7 million.

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) agreed to acquire 50.1% stake in Shenzhou Biology & Technology Co., Ltd. for RMB 501.7 million.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Now 21% undervalued

Investor sentiment improved over the past week

China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) announces an Equity Buyback for 23,500,000 shares, for CNY 431.7 million.

Third quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.31 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.27 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.26 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥1.01 in FY 2019)

China Resources Double-Crane Pharmaceutical Plans to Invest in Zhejiang Biotech Firm

New 90-day low: CN¥11.83

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

New 90-day low: CN¥11.90

New 90-day low: CN¥12.04

New 90-day low: CN¥12.51

Third quarter earnings released

New 90-day low: CN¥12.62

New 90-day low: CN¥12.77

Earnings released

New 90-day high - CN¥14.78

China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령